PHARMACY

Allergan and Stiefel partner over tazarotene

BY Drew Buono

CORAL GABLES, Fla. Allergan and Stiefel Laboratories have entered into an agreement to develop, manufacture, distribute, and promote dermatological products containing tazarotene, the active ingredient in Tazorac.

Tazorac is used to treat psoriasis and acne in a gel and cream form. Under the agreement, Stiefel will use its U.S. sales force to co-promote Allergan’s Tazorac to dermatologists. The company will also utilize the drug in several different ways to bring unique therapeutic options to the market as well as use Allergan’s proprietary technology.

“This is a great opportunity,” said Bill Humphries, chief commercial officer at Stiefel Laboratories. “Tazorac will provide the perfect complement to our acne portfolio, which also includes Duac, and it will allow Stiefel to offer best-in-class topical acne treatments to our customers. Given our long-standing and well-established presence in the dermatology arena, we will be able make an immediate and important impact with Tazorac.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mass. court levies combined $13.6 million against AstraZeneca, Bristol-Myers Squibb

BY Drew Buono

BOSTON A federal court in Massachusetts entered $12.9 million in damages against AstraZeneca and $695,594 against Bristol-Myers Squibb for the state’s class action members in a suit related to marketing the spread of certain drugs, according to law firms.

The judge, Patti B. Saris, found that AstraZeneca marketed the spread on its Zoladex drug, which is used to treat prostate cancer, selling it based on its profitability to doctors’ offices. She also found that less than 10 percent of Bristol-Myers Squibb’s sales were made within 5 percent of its list price, according to DowJones.

AstraZeneca and Bristol-Myers Squibb intend to appeal the ruling, which covers Massachusetts’s class-action participants.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Eli Lilly’s depression care program receives certification

BY Drew Buono

INDIANAPOLIS Eli Lilly has received Program Design Certification from the National Committee for Quality Assurance for its Tools that Empower Depression Care Management Program.

Tools that Empower Depression Care Management Program is designed for managed care organizations to assist in further driving the standard of patient care around major depressive disorder. It helps identify members with major depressive disorder and offers educational resources to support treatment.

“Tools that Empower is part of Lilly’s commitment to our customers to help reduce patient risk and create an environment of continuous improvement for patient care,” said Jack Bailey, vice president, Lilly’s Business to Business division. “The NCQA certification validates the helpful tools provided by the program.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES